Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04265872 · ClinicalTrials.gov registry record · Early Phase 1
Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC
A Early Phase 1 study of Breast Cancer, sponsored by Baylor Research Institute.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04265872 is a Early Phase 1 study of Breast Cancer that is actively recruiting participants, run by Baylor Research Institute. The registered enrollment target is 20 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04265872, a Early Phase 1 study of Breast Cancer, is actively recruiting participants, sponsored by Baylor Research Institute.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The hypothesis of this pilot trial is that administration of bortezomib will inhibit NHEJ in metastatic TNBC leading at the time of disease progression to metastases that are HR-deficient and sensitive to pembrolizumab and cisplatin therapy. The trial will include in depth analysis of the patients' TNBC genome and phosphoproteome to evaluate HR-proficiency and deficiency, and nuclear proteins that drive NHEJ, before and upon progression with bortezomib therapy.
Conditions Studied
Interventions
- DRUG Bortezomib; pembrolizumab and cisplatin injections--bortezomib followed by pembro/cis
Study Locations (1)
Texas
- Baylor University Medical Center, Baylor Charles A Sammons Cancer Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-10-15 |
| Est. Completion | 2027-03-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04265872
The ClinicalTrials.gov registry entry for NCT04265872 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Baylor Research Institute, which has 180 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Bortezomib; pembrolizumab and cisplatin injections--bortezomib followed by pembro/cis is the first listed.
NCT04265872 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04265872 about?
NCT04265872 is a clinical study titled "Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC". The hypothesis of this pilot trial is that administration of bortezomib will inhibit NHEJ in metastatic TNBC leading at the time of disease progression to metastases that are HR-deficient and sensitive to pembrolizumab and cisplatin therapy. The trial will include in depth analysis of the patients' ...
What is the current status of trial NCT04265872?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2020-10-15. Estimated completion is 2027-03-31.
What conditions does trial NCT04265872 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT04265872?
The interventions under investigation include: Bortezomib; pembrolizumab and cisplatin injections--bortezomib followed by pembro/cis (DRUG).
Who is sponsoring clinical trial NCT04265872?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04265872 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System
RECRUITING · Early Phase 1
-
Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy
RECRUITING · Early Phase 1
-
Neratinib in Combination With Ruxolitinib in Patients With mTNBC
RECRUITING · Early Phase 1
-
Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy
RECRUITING · Early Phase 1
-
FES BPET-DBT in Newly Diagnosed Breast Cancer
RECRUITING · Early Phase 1
-
Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.